Taner Korkmaz

Taner Korkmaz

Auto-generated profile, based on publicly available information

Taner Korkmaz

Acıbadem Research Institute of Senology, Acıbadem Mehmet Ali Aydınlar University, İstanbul, Türkiye

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2013 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
NKNimet Karadayı
Nimet Karadayı
NKNilufer Onak Kandemır
Nilufer Onak Kandemır
DYDilek Yavuzer
Dilek Yavuzer
TKTaner Korkmaz
Taner Korkmaz
GGGonca Gecmen
Gonca Gecmen
FKFuruzan Kokturk
Furuzan Kokturk
Background: Lymphatic metastasis is the most important parameter in the spread of gastric carcinomas. Nitric oxide (NO) is a signaling molecule that plays an important role in inflammation and carcinogenesis. In this study, the possible link between inducible nitric oxide synthase (iNOS) expression with lymphangiogenesis and the clinicopathological parameters of gastric carcinomas was investigated. Methods: In this study, iNOS expression and D2-40 (lymphatic endothelium-specific marker monoclonal antibody) reactivity were examined immunohistochemically in 41 gastric adenocarcinoma and 20 non-neoplastic gastric tissues. iNOS expression was scored semiquantitatively in the tumor parenchyma and stroma. D2-40-positive lymphatic vessels were used in the determination of lymphatic invasion and intratumoral and peritumoral lymphatic vascular density. Results: iNOS expression was higher in gastric carcinoma tissue compared with non-neoplastic tissue. Particularly, iNOS expression in tumor cells was found to be closely related to lymphangiogenesis and lymphatic metastasis. The density of lymphatic invasion as well as intratumoral and peritumoral lymphatic vascular density were positively correlated with lymph node metastasis. Conclusions: Our results suggest that iNOS-mediated NO formation plays an important role in gastric carcinogenesis, tumor lymphangiogenesis, and the development of lymphatic metastases. Inhibition of the NO pathway may be an alternative treatment of gastric carcinomas. Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1713572940104388.

7 June 2021 in Cancer Investigation
Verified
Journal Article
Closed access
ABAykut Bahçeci
Aykut Bahçeci
SPSemra Paydas
Semra Paydas
NANaziye Ak
Naziye Ak
FFFerhat Ferhatoğlu
Ferhat Ferhatoğlu
PSPınar Mualla Saip
Pınar Mualla Saip
NYNilgün Yildirim
Nilgün Yildirim
The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment.Retrospective analysis o...

1 April 2021 in European Journal of Breast Health
Verified
Journal Article
Closed access
NGNilgün Güldoğan
Nilgün Güldoğan
GIGul ESEN ICTEN
Gul ESEN ICTEN
FTFatma Tokat
Fatma Tokat
BTBurçin Tutar
Burçin Tutar
HKHalil KARA
Halil KARA
GDGökhan Demir
Gökhan Demir
Despite the high prevalence of lung cancer among other primary tumors, metastasis of this particular malignancy in the breast is very rare. We report three new cases of lung cancer with breast metastases and discuss radiological and clinical findings. Radiologically, each case displayed different characteristics. First, one of them had bilateral superficially and deeply located irregular lesions. Second, the patient presented with findings similar to inflammatory breast cancer. The third case had a circumscribed mass, resembling a benign complicated cyst. To guide clinicians for proper patient management, radiologists should be aware of the scope of typical and atypical imaging findings of metastatic involvement of the breast.

1 March 2020 in Balkan Medical Journal
Verified
Journal Article
Closed access
ADAtakan Demir
Atakan Demir
NMNil Kler Mandel
Nil Kler Mandel
SPSemra Paydas
Semra Paydas
GDGökhan Demir
Gökhan Demir
ÖEÖzlem Er
Özlem Er
GBGül Başaran
Gül Başaran
Background: The synthesis of CDK4/6 inhibitors with endocrine treatment in two series of treatment has been widely accepted as the standard for patients with estrogen receptor-positive metastatic breast cancer. In spite of this, the activity of CDK4/6 inhibitors in patients with metastatic breast cancer who have progressed despite receiving multiple lines of treatment is not well understood. Aims: To report the activity and safety of a CDK4/6 inhibitor (palbociclib) in patients in whom at least three lines of treatment for ER+ metastatic breast cancer had failed. Study Design: Multicenter retrospective observational cohort study. Methods: In this retrospective observational cohort study, we included 43 patients who received palbociclib after at least three lines of systemic treatment for ER+/HER2- metastatic breast cancer. Results: The median progression-free survival in our population was 7 months (25th-75th percentile, 4-10), and the median overall survival was 11 months (25th-75th percentile, 6-19). Although there were some adverse events, palbociclib was generally well tolerated, so dose reduction was needed for only six patients (14%). Conclusion: The efficacy of palbociclib among heavily treated hormone receptor-positive/HER2- patients with advanced breast cancer was acceptable in terms of clinical benefit, and it was generally well tolerated among this population.

25 December 2025 in European Journal of Breast Health
Verified
Journal Article
Open access
ETElif Şenocak Taşçı
Elif Şenocak Taşçı
ÖSÖzlem Sönmez
Özlem Sönmez
BOBaşak Oyan
Başak Oyan
TKTaner Korkmaz
Taner Korkmaz
IYİbRahim Yıldız
İbRahim Yıldız
YEYeşim Eralp
Yeşim Eralp
Breast cancer represents the most frequently diagnosed malignancy among women globally, with significant progress in systemic therapy, surgical techniques, and radiotherapy contributing to improved clinical outcomes. However, many clinical scenarios encountered in daily practice are not fully addressed by randomized trials, leaving persistent grey zones in the management of early-stage breast cancer. To meet these challenges, the multidisciplinary panel at Research Institute of Senology, Acıbadem University outlined experience-based recommendations for clinical situations typically faced in daily practice. Herein we aim to reflect both current evidence and institutional practice and provide practical guidance in areas where uncertainty persists. As breast cancer treatment continues to evolve, updates will be required to integrate emerging data and refine individualized patient care.